The estimated Net Worth of Robert J. Shovlin is at least $14.5 million dollars as of 25 May 2021. Mr. Shovlin owns over 130,604 units of Neogenomics stock worth over $2,448,147 and over the last 10 years he sold NEO stock worth over $10,774,218. In addition, he makes $1,284,100 as President - Clinical Services Division at Neogenomics.
Robert has made over 10 trades of the Neogenomics stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 130,604 units of NEO stock worth $5,134,043 on 25 May 2021.
The largest trade he's ever made was exercising 300,000 units of Neogenomics stock on 9 November 2018 worth over $1,437,000. On average, Robert trades about 54,393 units every 100 days since 2014. As of 25 May 2021 he still owns at least 150,101 units of Neogenomics stock.
You can see the complete history of Mr. Shovlin stock trades at the bottom of the page.
Robert J. Shovlin serves as President - Clinical Services Division of the Company. Mr. Shovlin has served as the President of our Clinical Services Division since September, 2016. Prior to this, he had served as our Chief Growth Officer since the acquisition of Clarient Inc. (“Clarient”) in 2015. From his hire date in October 2014 until the Clarient acquisition, Mr. Shovlin served as the Chief Operating Officer of NeoGenomics. From 2012 until October 2014, Mr. Shovlin served as Chief Development officer for Bostwick Laboratories, a provider of anatomic pathology testing services targeting urologists and other clinicians, where he was responsible for Sales, Marketing, Managed Care, Business Development, and Clinical Trials. From 2005 until 2011, he served in progressively more responsible positions, including President and Chief Executive Officer, for Aureon Biosciences, Inc., a venture-backed diagnostics company focused on developing novel and proprietary prostate cancer tests. Mr. Shovlin also served as Executive Director for Anatomic Pathology and Director of Managed Care for Quest Diagnostics from 2003 until 2005, and held sales leadership positions at Dianon Systems from 1997 until 2003. Mr. Shovlin served as a Captain, Infantry Officer in the United States Marine Corps from 1992 until 1997 where he served as a Platoon and Company Commander with 1st Battalion 4th Marines and as an Instructor and Staff Platoon Commander at the Basic School. He holds a Bachelor of Science Degree from Pennsylvania State University, and a Masters of Business Administration from Rutgers University.
As the President - Clinical Services Division of Neogenomics, the total compensation of Robert Shovlin at Neogenomics is $1,284,100. There are 1 executives at Neogenomics getting paid more, with Douglas VanOort having the highest compensation of $3,648,730.
Robert Shovlin is 49, he's been the President - Clinical Services Division of Neogenomics since 2016. There are 20 older and 5 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Robert's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van et Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: